Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (46149)	6/24/1999 8:59:00 AM
From: Burjis S.	Read Replies (1) \| Respond to of 120523

Kendall .... LGND historically for the past 2 years has always been disappointing for it's investors, it was a very highly hyped stock on SI in the past and I have been burnt on this one. The only news I got on this one is from yesterday as below: SAN DIEGO, June 23 (Reuters) - Ligand Pharmaceuticals Inc. <LGND.O> on Wednesday said it has applied to the U.S. Food and Drug Administration (FDA) for approval for its new lymphoma drug, Targretin. The company said the capsules may be taken once daily by patients with cutaneous T-cell lymphoma, which is a type of cancer that affects white blood cells involved in the body's immune system. Ligand said it received approval from the FDA to file Targretin capsules under orphan drug designation for this indication and has requested priority review status of the filing. If the application is granted priority review status, the FDA is expected to respond within six months of the submission. 18:29 06-23-99